Trial Profile
Traumakine for prevention of mortality among operated rupture of abdominal aorta aneurysm (RAAA) patients
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 03 Apr 2017
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Aneurysm
- Focus Adverse reactions; Therapeutic Use
- 03 Apr 2017 New trial record
- 29 Mar 2017 According to a Faron Pharmaceuticals media relase, the company has initiated filing of clinical trial application for the use of Traumakine in a second indication for the prevention of mortality among operated RAAA (Rupture of Abdominal Aorta Aneurysm) patients.